<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hong S</submitter><funding>the Natural Science Foundation of Shanxi Province</funding><funding>Shanxi Province doctoral graduates and postdoctoral researchers come to work in Shanxi Province to reward the fund scientific research project</funding><funding>the earmarked fund for Modern Agro-industry Technology Research System</funding><funding>Shanxi Agricultural University Doctoral Research Initiation Project</funding><pagination>5313</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12693271</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(23)</volume><pubmed_abstract>Synergetic therapeutic study using multifunctional nanoplatforms has been developed as an innovative modality for effective cancer treatment to improve the clinical efficiency of anticancer drugs and reduce severe off-target side effects. Herein, an artificial nanoplatform (denoted as PPy-RhB-PDA-CD-LA) was prepared by grafting β-cyclodextrin (β-CD) derivatives and lactobionic acid (LA) on the surface of rhodamine B (RhB)-doped polypyrrole nanoparticles (PPy-RhB NPs) using polydopamine (PDA) as the intermediate linker. Doxorubicin (DOX) was selected and successfully loaded onto the nanoplatforms with a high loading content of 327 mg/g. Furthermore, significant NIR light-triggered release of DOX was observed in a weak acidic tumor microenvironment. The nanoplatform exhibited superior photostability with a high photothermal effect of 51.7% under irradiation by a 808 nm laser and a competent temperature sensitivity (SR is 1.44% °C&lt;sup>-1&lt;/sup>) under a single wavelength excitation. MTT assay against SMMC-7721 cells clearly illustrated that the nanoplatform had low cytotoxicity at a high level (200 μg/mL) after 24 h and high therapeutic efficacy of chemo-phototherapy. Thus, it is highly promising for use in biomedical applications.</pubmed_abstract><journal>Materials (Basel, Switzerland)</journal><pubmed_title>β-Cyclodextrin-Grafted Polypyrrole-Rhodamine B Nanoplatforms for Drug Delivery and Image-Guided Photothermal Therapy In Vitro.</pubmed_title><pmcid>PMC12693271</pmcid><funding_grant_id>SXBYKY2022076</funding_grant_id><funding_grant_id>202203021212443</funding_grant_id><funding_grant_id>2021BQ122</funding_grant_id><funding_grant_id>2025CYJSTX10</funding_grant_id><pubmed_authors>Shuang S</pubmed_authors><pubmed_authors>Li R</pubmed_authors><pubmed_authors>Guo S</pubmed_authors><pubmed_authors>Jiao Y</pubmed_authors><pubmed_authors>Lei P</pubmed_authors><pubmed_authors>Dong C</pubmed_authors><pubmed_authors>Hong S</pubmed_authors></additional><is_claimable>false</is_claimable><name>β-Cyclodextrin-Grafted Polypyrrole-Rhodamine B Nanoplatforms for Drug Delivery and Image-Guided Photothermal Therapy In Vitro.</name><description>Synergetic therapeutic study using multifunctional nanoplatforms has been developed as an innovative modality for effective cancer treatment to improve the clinical efficiency of anticancer drugs and reduce severe off-target side effects. Herein, an artificial nanoplatform (denoted as PPy-RhB-PDA-CD-LA) was prepared by grafting β-cyclodextrin (β-CD) derivatives and lactobionic acid (LA) on the surface of rhodamine B (RhB)-doped polypyrrole nanoparticles (PPy-RhB NPs) using polydopamine (PDA) as the intermediate linker. Doxorubicin (DOX) was selected and successfully loaded onto the nanoplatforms with a high loading content of 327 mg/g. Furthermore, significant NIR light-triggered release of DOX was observed in a weak acidic tumor microenvironment. The nanoplatform exhibited superior photostability with a high photothermal effect of 51.7% under irradiation by a 808 nm laser and a competent temperature sensitivity (SR is 1.44% °C&lt;sup>-1&lt;/sup>) under a single wavelength excitation. MTT assay against SMMC-7721 cells clearly illustrated that the nanoplatform had low cytotoxicity at a high level (200 μg/mL) after 24 h and high therapeutic efficacy of chemo-phototherapy. Thus, it is highly promising for use in biomedical applications.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-05-26T11:03:41.54Z</modification><creation>2026-05-24T03:11:39.163Z</creation></dates><accession>S-EPMC12693271</accession><cross_references><pubmed>41374154</pubmed><doi>10.3390/ma18235313</doi></cross_references></HashMap>